secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001628280-25-001239
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma licenses mavorixafor to Norgine for €28.5M upfront, up to €226M milestones
--------------------------------------------------------------------------------

- Exclusive license for Europe, Switzerland, UK, Australia, New Zealand; X4 retains rest of world.
- X4 receives €28.5M upfront; up to €226M in regulatory, commercial, sales milestones.
- Escalating double-digit royalties up to mid-twenties on net sales in licensed territories.
- X4 continues Phase 3 4WARD trial in chronic neutropenia; Norgine handles commercialization.
- MAA for WHIM syndrome to be submitted to EMA shortly; mavorixafor has Orphan Drug Designation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828025001239/0001628280-25-001239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828025001239/xfor-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-001239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer